Genentech won FDA approval on Friday to market Lucentis to restore sight in a significant percentage of patients afflicted with a common eye disease that is the major cause of blindness in the elderly; wet age-related macular degeneration.
The back story to this is here and here.
Lucentis has a price per dose of $1,950.
Doses of Avastin are available to doctors at $50 or less from compounding pharmacies that divide up vials of the cancer drug into the much smaller amounts needed for eye treatment.
more here
No comments:
Post a Comment